New UK fund cornerstoned by £50 million investment from the British Business Bank, through its Enterprise Capital Funds (ECF) programme Epidarex Capital III UK LP
Combines Best-in-Class Bone Repair with Intraoperative Ease-of-Use for Spine and Trauma Bone Grafting Applications Aberdeen, UK, 17 June 2020 – SIRAKOSS Ltd, a developer of
71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs.
Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital,